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The Ca2+ sensor calmodulin (CaM) regulates cardiac ryanodine receptor (RyR2)-mediated
Ca2+ release from the sarcoplasmic reticulum. CaM inhibits RyR2 in a Ca2+-dependent
manner and aberrant CaM-dependent inhibition results in life-threatening cardiac arrhyth-
mias. However, the molecular details of the CaM–RyR2 interaction remain unclear. Four
CaM-binding domains (CaMBD1a, -1b, -2, and -3) in RyR2 have been proposed. Here,
we investigated the Ca2+-dependent interactions between CaM and these CaMBDs by
monitoring changes in the fluorescence anisotropy of carboxytetramethylrhodamine
(TAMRA)-labeled CaMBD peptides during titration with CaM at a wide range of Ca2+
concentrations. We showed that CaM bound to all four CaMBDs with affinities that
increased with Ca2+ concentration. CaM bound to CaMBD2 and -3 with high affinities
across all Ca2+ concentrations tested, but bound to CaMBD1a and -1b only at Ca2+ con-
centrations above 0.2 mM. Binding experiments using individual CaM domains revealed
that the CaM C-domain preferentially bound to CaMBD2, and the N-domain to CaMBD3.
Moreover, the Ca2+ affinity of the CaM C-domain in complex with CaMBD2 or -3 was so
high that these complexes are essentially Ca2+ saturated under resting Ca2+ conditions.
Conversely, the N-domain senses Ca2+ exactly in the transition from resting to activating
Ca2+ when complexed to either CaMBD2 or -3. Altogether, our results support a binding
model where the CaM C-domain is anchored to RyR2 CaMBD2 and saturated with Ca2+
during Ca2+ oscillations, while the CaM N-domain functions as a dynamic Ca2+ sensor
that can bridge noncontiguous regions of RyR2 or clamp down onto CaMBD2.
Introduction
Cardiac ryanodine receptors (RyR2s) are large intracellular Ca2+ channels that control the release of
Ca2+ from the sarcoplasmic reticulum (SR) in cardiomyocytes [1]. Excitation of cardiomyocytes
causes a small influx of extracellular Ca2+ through voltage-gated Ca2+ channels (CaV1.2s). This initial
rise in cytosolic Ca2+ activates RyR2 and results in a Ca2+-induced Ca2+ release (CICR) sufficient to
cause myofilament contraction [1,2]. Equally important, RyR2 inactivation allows for replenishing of
the SR Ca2+ store in preparation for the next cardiomyocyte excitation [1–3]. RyR2 forms homotetra-
meric channels that arrange in spatially well-defined Ca2+ release units [1]. This organization means
that the concentration of free Ca2+ in the cytosol near RyR2 oscillates between ∼0.2 mM at diastole
and 200–400 mM during CICR and systole [2,4,5]. The cytosolic Ca2+-sensing protein calmodulin
(CaM) binds to RyR2 and inhibits the release of Ca2+ in a Ca2+-dependent manner [1,6–10]. CaM
consists of two Ca2+-binding domains (the N- and C-domains) that each contains two EF-hands, and
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thereby enables the binding of four Ca2+ ions. The two CaM domains display distinct Ca2+ affinities and -kinetics,
and are connected by a flexible linker region that allows them to make independent interactions [10–14].
Importantly, the skeletal muscle ryanodine receptor (RyR1) and RyR2 are differentially regulated by CaM.
Whereas both channels display Ca2+-dependent regulation and are inhibited by CaM at higher Ca2+ levels,
RyR1 is activated by CaM at low Ca2+ levels, while RyR2 is inhibited [6,15–17]. One CaM-binding domain
(CaMBD) has been demonstrated to be central for the interaction between CaM and both RyR1 and RyR2, and
also for the inhibition by CaM [6,8,10,15–18]. However, this CaMBD (RyR2 Arg-3581–Pro-3607, termed
CaMBD2 in this study) is highly conserved between RyR isoforms (Figure 1) and is therefore unlikely to consti-
tute the site of differential regulation by CaM. As such, the site(s) responsible for the different effects of CaM
on the two RyR channels remain(s) unresolved.
Even though the molecular details of the interaction between RyR2 and CaM are not fully understood, it has
been demonstrated that Ca2+ saturation of both CaM domains is required for full inhibitory effect [8,10,15,18–21].
Moreover, the Ca2+ affinities of each CaM domain in the presence of RyR2 CaMBD2 differ by ∼30-fold, with
the C-domain having the highest Ca2+ affinity, and implies distinct roles of each domain in the regulation of
RyR2 [10]. Experiments examining the binding of CaM to RyR2 fragments support up to four CaMBDs, here
referred to as CaMBD1a, -1b, -2, and -3 (Figure 1 and Table 1) [9,22–31]. Recently, Lau et al. [28] analyzed
the interaction between CaM and RyR2 CaMBD1a, -2, and -3 by isothermal titration calorimetry (ITC). The mea-
surements were carried out at Ca2+-free [10 mM ethylenediaminetetraacetic acid (EDTA)] and Ca2+-saturating
(10 mM CaCl2) conditions, and all CaMBDs were fused to maltose-binding protein (MBP). CaMBD1b has so far
not been investigated beyond CaM overlay assays [22].
In this study, we extended the investigation of the interaction between CaM and the four proposed RyR2
CaMBD peptides using a fluorescence anisotropy-based titration method. This method allowed us to explore
the Ca2+ dependency of the interaction between CaM and RyR2 CaMBDs across a broad range of free Ca2+
concentrations ([Ca2+]), including the physiologically relevant range for the cardiomyocyte cytosol. Our results
showed that the strength of each CaM–CaMBD interaction is highly Ca2+-dependent with higher [Ca2+] con-
sistently resulting in higher affinity of CaM for the CaMBDs. Also, the interaction affinities and their Ca2+
dependencies varied significantly between the different CaMBDs, with CaM displaying the highest affinity
for CaMBD2 and -3. Measurements using isolated CaM domains established that the CaM C-domain prefer-
entially binds to CaMBD2 and the N-domain to CaMBD3. Finally, the CaM affinity for Ca2+ was markedly
Figure 1. Overview of CaMBDs of RyR.
ClustalW protein sequence alignment of the three human RyR isoforms (hRyR1–3). Amino acids that are identical between
hRyR1-3 are highlighted in gray and amino acids that are resolved in the cryo-EM structure of rabbit RyR1 (PDB: 3J8H) are
underlined. The dots above the alignment indicate amino acid intervals of five according to the RyR2 sequence.
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increased in the presence of the CaMBDs, compared with free CaM, and differed markedly between the two
CaM domains.
Experimental procedures
Visualization of CaMBDs in the RyR structure and protein sequence alignment
The crystal structure of Ca2+–CaM in a complex with RyR1 CaMBD2 (PDB: 2BCX) was juxtaposed with the
high-resolution cryo-EM structure of the closed state of rabbit RyR1 (rRyR1, PDB: 3J8H) [29,32]. The indicated
position and orientation of CaM is according to the existing literature [23–27]. For protein sequence alignments
and comparisons, rRyR1 and human RyR1–3 (hRyR1–3) were aligned using the ClustalW algorithm within the
CLC Main Workbench 6 (CLC Bio, version 6.9.1) [33]. UniprotKB accession numbers: P11716, P21817,
Q92736, and Q15413. The alignment of rRyR1 and hRyR2 was used to identify the hRyR2 amino acids equiva-
lent to those in the rRyR1 cryo-EM structure and the alignment of hRyR1–3 was used to determine the conser-
vation of CaMBDs between hRyRs. Delimitation of the protein regions corresponding to CaMBD1a,
CaMBD1b, CaMBD2, and CaMBD3 were adopted from previous studies [15,22,28,34].
Protein expression and purification
Expression and purification of full-length CaM and CaM domains was done as previously described and sum-
marized below [28,35].
Full-length CaM (CaM: A2-K149) was expressed in Escherichia coli (E. coli) Rosetta (DE3) from a modified
pMal vector with an N-terminal MBP and a tobacco etch virus (TEV) cleavage site. The MBP–TEV–CaM
fusion protein was purified on an amylose affinity column (New England Biolabs) and subsequently cleaved by
a TEV protease. Following cleavage, CaM, TEV, and MBP were separated by anion ion exchange chromato-
graphy using a Q-sepharose column (GE Healthcare). The CaM-containing fractions were pooled and concen-
trated before removing residual Ca2+ by adding 20 mM EDTA to the sample prior to applying it to a Superdex
75 size exclusion column (GE Healthcare).
CaM domains (CaM N-domain: SNAWGG-M1-R75; CaM C-domain: SNA-K76-K149) were expressed in
E. coli Rosetta (DE3) from a modified pET28 vector with an N-terminal His-tag and a TEV cleavage site. The
His–TEV–CaM protein was first purified by immobilized metal affinity chromatography (IMAC) using a
Poros20 MC column (Applied Biosystems) and subsequently cleaved with a His-tagged TEV protease. The
His-tagged TEV protease and cleavage product were removed in a second IMAC step and the flow-through,
containing CaM domain, was further purified on a phenyl-sepharose and a Q-sepharose column (GE
Healthcare). Lastly, the CaM domain pool was concentrated and applied to a Superdex 200 size exclusion
column (GE Healthcare) for a final purification and Ca2+ removal step. The identity, purity, and integrity of
each protein preparation were confirmed by SDS–PAGE (sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis) and MALDI-TOF (matrix-assisted laser desorption/ionization-time-of-flight) mass spectrometry of
trypsin-digested proteins and entire nondigested domains. Protein concentrations were measured using
Table 1 RyR2 CaMBD peptides used in the present study
CaMBD2(+) peptides were used for determining the importance of CaMBD2 hydrophobic anchors. Numbering corresponds to
human RyR2 (UniprotKB Q92736).
Nomenclature RyR2 residues Peptide sequence (length) Mutation/modification Ref.
CaMBD1a F1942 – R1966 RFRYNEVMQALNMSAALTARKTKEF (25) [28,34]
CaMBD1b D2022 – S2052 DLTIRGRLLSLVEKVTYLKKKQAEKPVESDS (31) [22,46]
CaMBD1b + P D2022 – S2052 DLTIRGRLLSLVEKVTYLKKKQAEKPVESDS (31) S2031 phosphorylated [22,46]
CaMBD2 R3581 – P3607 RSKKAVWHKLLSKQRKRAVVACFRMAP (27) [28,44]
CaMBD2(+) R3581 – L3611 RSKKAVWHKLLSKQRKRAVVACFRMAPLYNL (31) [10,21,35]
CaMBD2(+)-W/A R3581 – L3611 RSKKAVAHKLLSKQRKRAVVACFRMAPLYNL (31) W3587A
CaMBD2(+)-F/A R3581 – L3611 RSKKAVWHKLLSKQRKRAVVACARMAPLYNL (31) F3603A
CaMBD3 F4246 – V4276 FALRYNILTLMRMLSLKSLKKQMKKVKKMTV (31) [28]
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absorption at 280 nm (extinction coefficient 2560 cm−1 M−1 for intact CaM and the CaM C-domain; 5690
cm−1 M−1 for the N-domain, due to the added Trp residue).
Peptides corresponding to RyR2 CaMBDs
Peptides with an N-terminal 5-TAMRA (5-carboxytetramethylrhodamine) label were from Proteogenix (>95%
purity, Table 1). Peptide concentrations were determined from the 5-TAMRA absorption at 556 nm (extinction
coefficient 103 000 cm−1 M−1). Stock solutions were kept in 5% acetonitrile and 0.1% trifluoroacetic acid. For
investigating CaMBD2 hydrophobic anchor residue effects, an elongated version of CaMBD2 (CaMBD2(+))
was used along with peptide variants where the Trp or Phe residues were replaced with Ala (Table 1).
pH- and Ca2+-buffered solutions
pH- and Ca2+-buffered solutions (pCa buffers) contained 50 mM HEPES [4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid], 100 mM KCl, 0.5 mM EGTA [ethylene glycol-bis(β-aminoethyl ether)-N,N,N0,
N0-tetraacetic acid], and 2 mM NTA (nitrilotriacetic acid) at pH 7.2 (25°C) and variable concentrations of
CaCl2. Before dilution and pH adjustment, the batch of buffer was split and one aliquot was added CaCl2 to
3 mM total Ca2+ ([Ca2+]tot). Mixing of various amounts of the pCa buffers with and without 3 mM CaCl2 to
different [Ca2+]tot established various EGTA/NTA-buffered free Ca
2+ concentrations ([Ca2+]) [36]. In practice,
1.5× concentrated pCa buffer stocks were prepared, and CaMBD and reducing agent (0.3 mM DTT) were
added to the double distilled water used for diluting these concentrated buffers. The calculated buffer ionic
strength was 150 mM, and the [Ca2+] was verified by Ca2+ titrations in the presence of CaM or CaM/RyR2–
CaMBD2 [10].
Titrations of CaMBD peptides with CaM, or CaM domains, at discrete Ca2+
concentrations
A two-dimensional titration assay was employed to determine the affinity of CaM, or isolated CaM domains,
for binding to RyR2-derived CaMBD peptides at 16 discrete [Ca2+] [37]. This assay was based on measuring
the change in the fluorescence anisotropy (FA) signal of the 5-TAMRA-labeled peptides occurring when CaM
or CaM domain binds (Figure 3A.2). Measurements were done in 384-well microtiter plates (16 × 24 wells)
with the CaMBD concentrations kept constant (∼50 nM), and varying the CaM concentration in 23 serial dilu-
tion steps across the columns of one plate row (Figure 3A.1). Titrations were done in pCa buffer (see above),
which allowed for mixing high and low [Ca2+]tot solutions to obtain specific [Ca
2+], and each of the 16 rows in
the microtiter plate was used for a defined [Ca2+] condition (Figure 3A.1–2). All in all, each microtiter plate
allowed for 24 titrations points for CaM concentrations at each of the 16 different [Ca2+], i.e. 16 CaM–CaMBD
titration curves (Figure 3B.1–2).
In practical detail, 3 ml of purified CaM (∼600–1200 mM) was manually aliquoted to each well in column 1
of a 384-well low-binding microtiter plate (Corning, Cat. #3575). Using an automated liquid handling robot
(Hamilton, Microlab STARlet), 65 ml of the 16 different pCa buffers ([Ca2+] = 0.3 nM–400 mM), including
50 nM TAMRA-labeled CaMBD and 0.3 mM DTT, were aliquoted into each row in column 1, containing
CaM. Next, 30 ml of each of the same 16 different pCa buffers were aliquoted into the 23 empty wells in each
row. Finally, CaM in column 1 was serial diluted by row-wise transferring 38 ml volumes to the adjacent
column, including 4 × 30 ml pre-mixing during aspiration. pCa buffer (38 ml) was discarded from the last
column and produced 24 dilutions of CaM for each [Ca2+]. The titration procedure completed in <50 min and
the protein dilution factor (38 : 68 ml) between columns was verified using fluorescein (Sigma–Aldrich, Cat.
#F6377) in 10 mM NaOH. Immediately after mixing, the FA signal was measured in a fluorescence plate reader
(Tecan, Infinite M1000) with excitation and emission wavelengths at 530 and 582 nm with 5 and 20 nm
bandwidths, respectively. The signal gain was fixed at 95, the settling time was set to 200 ms, the FA G-factor
to 1.144 (fluorescein determined), and 20 flashes were used per measurement. All combinations of CaM, iso-
lated CaM domains, and CaMBDs were measured in at least duplicate. Plate mixing and measurements were
done at 25°C.
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Titration curve analysis for determining the affinity of CaM or CaM domains
for binding to CaMBD peptides
CaM and CaM domains were expected to bind RyR2 CaMBD peptides (P) stoichiometrically [28] with the
binding affinity expressed as the apparent CaM/CaMBD complex (PCaM) dissociation constant (KD), i.e.
PCaM  Pþ CaM
KD ¼ [P]  [CaM][PCaM]
where [P], [CaM], and [PCaM] are the concentrations of free CaMBD, free CaM, and CaM/CaMBD complex,
respectively. This simple binding model assumes one type of CaM–CaMBD interaction, i.e. characterized by















where [P]tot and [CaM]tot are the total concentrations of CaMBD peptide and CaM, respectively. For each plate
row in the titration scheme described above, a titration curve of FA as a function of [CaM]tot was obtained
(Figure 3A.1–3). The measured FA signal consists of the FA signal from the free CaMBD peptide (FAP) and
the FA signal from the CaM/CaMBD complex (FAPCaM), hence
FA ¼ FAP  (1 Y)þ FAPCaM  Y (2)
where FAP and FAPCaM represent the minimum (entirely free CaMBD peptide) and maximum (entirely bound
CaMBD peptide) FA signal. Substituting the expression for Y in equation 1 for Y in equation 2 and isolating
for FA allowed for fitting the 1 : 1 binding model to each titration curve and thus obtaining a value of KD at
that [Ca2+] (Figure 3A.3). KD as a function of [Ca
2+] was obtained by fitting each row-wise titration curve
(Figure 3B.1–3) using nonlinear regression in GraphPad Prism 6.07. A potential interference of the 5-TAMRA
label with the binding of CaM to the CaMBDs was excluded by a titration of free 5-TAMRA with CaM which
showed no binding (data not shown).
CaM binding to RyR2 CaMBD1a did not fit well with a 1 : 1 interaction at [Ca2+] >800 nM, yet the observed
maximum FAPCaM values were highly similar to those for CaM bound to CaMBD1b, CaMBD2 (at low [Ca
2+],
see ‘Results’), and CaMBD3 peptides (FA range 240–260). By inferences, the binding of CaM to CaMBD1a was
therefore likely an 1 : 1 interaction since the FA signal correlates with the protein–peptide geometric size [38].
The simplest model of 1 : 1 interaction assuming more than one type of CaM–CaMBD interaction has two dif-
ferent modes of CaM binding to CaMBD, each characterized by their own affinity and KD values (KDI and







[CaM] is not explicitly known in the titrations, but, for low-affinity interactions, [CaM] ≈ [CaM]tot is a good
approximation, and model fitting for CaMBD1a at [Ca2+] > 800 nM was done with this alternate expression for
Y in equation 2. We considered only the first mode of CaM–CaMBD1a interaction with the highest affinity of
the two (i.e. KDI), given that the KDII values were 5–25-fold higher than KDI.
Differences in the fitted KD values for CaM binding to the various CaMBD peptides were evaluated using
the conservative measure of nonoverlapping 95% confidence intervals (Supplementary Tables S1 and S2).
Anisotropy signals depend on the fluorescence emitter tumbling rate which, in turn, depends on the geometric
size of the CaMBD peptide and CaM/CaMBD complex in solution [38]. However, in our experiments, the total
fluorescence intensity of the 5-TAMRA probe was enhanced by Ca2+–CaM binding to CaMBD2 (data not
© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 197
Biochemical Journal (2019) 476 193–209
https://doi.org/10.1042/BCJ20180545
shown). This property did not interfere with the measurement of Y via the FA signal, but did impede an accur-
ate determination of the CaM/CaMBD2 complex size based on the FAPCaM signal.
Estimation of apparent Ca2+ affinities of CaM–peptide complexes
We determined the apparent affinities of CaM/CaMBD complexes for Ca2+ under conditions with an excess
of CaM. In practice, FA signals as a function of [Ca2+] (column-wise curves) were extracted for a specific
CaM : peptide ratio (∼4 for full-length CaM and ∼40 for isolated CaM domains):
FA ¼ FAlowCa  (1 Y)þ FAhighCa  Y (4)
where FAlowCa and FAhighCa represent the FA signal at the lowest and highest [Ca
2+], respectively, for each par-
ticular CaM concentration. These curves were fitted to a generic Hill model [39]:
Y ¼ 1
(appKD=[Ca2þ])
n þ 1 (5)
where Y is the fractional saturation of CaM/CaMBD complex with Ca2+, n the Hill coefficient, and appKD is
the [Ca2+] at half-saturation. Substituting the expression for Y in equation 4 for Y in equation 5 allowed for
fitting the Hill model and thus obtaining an appKD for Ca
2+-binding to CaM/CaMBD complexes. Fitting was
performed to the raw FA signals as a function of [Ca2+] using nonlinear regression in GraphPad Prism 6.07.
The significance of the differences in the fitted appKD for CaM and isolated CaM domains was evaluated using
the conservative measure of nonoverlapping 95% confidence intervals (Supplementary Table S3). The fit was
visualized using normalized fractional saturation (Figure 8).
Results
Visualization of CaM and CaMBDs in the three-dimensional structure of RyR
The ability of CaM to interact with the four suggested CaMBDs was evaluated by comparing the locations of
each CaMBD in the rabbit RyR1 (rRyR1) cryo-EM structure with the demonstrated CaM-binding site around
CaMBD2 (Figure 2). The size of CaM relative to the RyR channel is indicated in Figure 2 by juxtaposing the
channel and the crystal structure of Ca2+-saturated CaM in complex with the RyR1 CaMBD2 (CaM/
RyR1CaMBD2). The suggested positioning of CaM as well as the orientation of its two domains are based on
information from the available literature (Figure 2) [24–26,29,32]. Moreover, the orientation of CaMBD2 in the
CaM/RyR1CaMBD2 complex was aligned with the positions of resolved amino acids most adjacent to
CaMBD2 in the RyR1 structure.
Unfortunately, none of the four CaMBDs are fully resolved in the current RyR1 or RyR2 cryo-EM structures
[29,30,40–43]. Instead, the amino acids closest to either end of each CaMBD were individually colored and
labeled with numbers corresponding to the human RyR2 sequence (Figures 1 and 2 and Table 1). In this way,
the general locations of each CaMBD could be reasonably inferred. For simplicity, RyR amino acid numbering
corresponding to the human RyR2 sequence is used in this manuscript.
The three N-terminal amino acids of RyR2 CaMBD1a (Arg-1941, Phe-1942, and Arg-1943) are resolved and
visible in the structure, but the adjacent RyR region from Tyr-1944 to Leu-1997 is unresolved (Figure 2, blue
markings). CaMBD1b is largely resolved with Leu-2023 to Tyr-2038 visible in the RyR structure (Figure 2, red
markings). The first N-terminal RyR2 CaMBD1b residue, Asp-2022, is part of the unresolved Glu-2013 to
Asp-2022 region, and the C-terminal part of human RyR2 CaMBD1b (Leu-2039 to Ser-2052) is in the unre-
solved Leu-2039 to Ser-2056 region. Amino acids corresponding to CaMBD2 are all within the unresolved
Gln-3527 to Leu-3611 region in the RyR structure. However, Pro-3612 is visible, indicating an approximate
location for CaMBD2 (Figure 2, green markings). The location of CaMBD3 is poorly defined with all amino
acids encompassed in the 278 amino acid long unresolved human RyR2 Ser-4207 to Ile-4484 region. The
resolved human RyR2 amino acid closest to CaMBD3 is Ile-4206, which is 39 residues N-terminal to CaMBD3
Phe-4246 (Figure 2, orange markings).
Based on previous studies, CaM binds inside a pocket underneath the RyR helical domains (HD1–2) and
between the central and handle domains (Figure 2) [29]. With this positioning, CaM is in close vicinity of RyR
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CaMBD1a, -1b, and -2, all located in, or close to, the handle domain. Additionally, RyR CaMBD2 appeared to
span this CaM-binding pocket [44]. In comparison, the resolved residues closest to RyR CaMBD3 were further
away from the CaM-binding pocket. However, assuming the 39 amino acids between human RyR2 Ile-4206
and Phe-4246 of CaMBD3 fold into a regular α-helix, this would span 59 Å (3.6 amino acids/turn, pitch of
5.4 Å) and thereby easily be able to extend to within the CaM-binding pocket (Figure 2).
In summary, investigating the approximate positions of the CaM-binding sites in the high-resolution RyR
cryo-EM structure support that CaMBD1–3 are all within the range of the proposed CaM-binding pocket in
RyR. Moreover, the lack of cryo-EM structure resolution, especially around CaMBD2 and -3, is consistent with
these regions containing disordered, flexible CaMBDs likely to be accessible for CaM binding.
CaM binds to RyR2 CaMBD2 and -3 with high affinities at physiological Ca2+
concentrations
We titrated CaM in the presence of TAMRA-labeled CaMBD peptides at 16 discrete free Ca2+ concentrations
([Ca2+] = 0.3 nM–400 mM) (Figure 3 and Table 1). Binding of CaM to the CaMBD peptides was monitored as
an increase in the FA of TAMRA. A protein–peptide binding model was fitted at each Ca2+ concentration to
determine the apparent Ca2+-dependent affinities (KD) of the four CaM–CaMBD interactions (Figures 3 and 4,
and Supplementary Table S1). Generally, this assay allowed us to reliably measure affinities from ∼1 nM to
5 mM.
Binding curve analyses revealed that CaM bound to CaMBD2 and -3 with high affinities that increased with
increasing [Ca2+] (Figure 5 and Supplementary Table S1). In fact, CaM affinities for CaMBD2 or -3 peptides
were too high for reliable model fitting at [Ca2+] >0.2 mM and >0.4 mM, respectively (KD < 1 nM). The CaM
affinity for CaMBD2 increased 390-fold (KD from 390 to 1 nM) when [Ca
2+] was raised from 0.3 to 200 nM.
Similarly, the CaM affinity for CaMBD3 increased 76-fold (KD from 530 to 7 nM) in the same [Ca
2+] range.
Noteworthy, the CaM affinity for CaMBD2 was 2- to 9-fold higher than that for CaMBD3 in the low [Ca2+]
range from 13 to 200 nM where a direct comparison was possible. This indicates that CaM preferentially binds
to CaMBD2 at least in the low physiological [Ca2+] range.
Figure 2. Approximate locations of CaMBDs in the rabbit RyR1 (rRyR1) structure.
Ca2+-saturated CaM (purple) bound to RyR1 CaMBD2 (green) (PDB: 2BCX) was juxtaposed with the 3.8 Å resolution cryo-EM
structure of the closed-state rabbit RyR1 homotetramer (PDB: 3J8H) [29,32]. One RyR1 monomer is shown in yellow surface
representation, and the other three monomers as gray semi-transparent secondary structure schematics. The CaMBDs are not
fully resolved, but the nearest resolved N- and C-terminal amino acids are marked by sequence position and color: CaMBD1a
in blue, CaMBD1b in red, CaMBD2 in green, and CaMBD3 in orange. The labeled amino acid positions are numbered
according to the equivalent human RyR2 positions.
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CaM binds to RyR2 CaMBD1a and -1b markedly weaker than to CaMBD2 and
-3 at physiological Ca2+ concentrations
The CaM affinities for CaMBD1a or -1b were substantially lower than those for CaMBD2 or -3, with binding
only detectable at ≥0.4 mM and ≥0.2 mM [Ca2+], respectively (Figure 5 and Supplementary Table S1).
Nonetheless, the binding of CaM to both CaMBD1a and -1b was clearly Ca2+-dependent and affinities
increased 34- and 42-fold, respectively, with the elevation of [Ca2+] from 0.4 to 400 mM. On average, the CaM
affinity for CaMBD1b was 5-fold greater than that for CaMBD1a in the [Ca2+] range from 0.4 to 400 mM.
Interestingly, phosphorylation of the RyR2 Ser-2031 present in CaMBD1b (CaMBD1b + P) lowered the affinity
for CaM by ∼3-fold. Noteworthy, the CaM affinities for CaMBD1a, -1b, and -1b + P were approximately three
orders of magnitude lower than those for CaMBD2 or -3 in the [Ca2+] range from 0.2 to 0.4 mM where a
direct comparison was possible. These data demonstrate that out of the four CaMBDs investigated, CaM prefer-
entially binds to CaMBD2 or -3 throughout the entire range of [Ca2+].
CaM N- and C-domains do not contribute equally to the interactions with
CaMBD2 or -3
Domain-wise contributions to the interaction between CaM and RyR2 CaMBD2 or -3 were investigated by
determining the affinities of the isolated CaM N- or C-domain for either peptide (Figure 6 and Supplementary
Table S2). Generally, each individual CaM domain bound to CaMBD2 and -3 with lower affinities than full-
length CaM. Moreover, the CaM N-domain bound with much lower affinity than the C-domain, and binding






Figure 3. Measurement and analysis of titration curves for the determination of Ca2+-dependent dissociation constants (KD).
(A) Simplified measurement and analysis example. Each row in the microtiter plate (A.1) contained a titration series of peptide
with decreasing protein concentration (columns 1–24) at one [Ca2+]. Measuring the FA signal from each well in the row gave a
titration curve, i.e. the FA signal as a function of the total protein concentration ([Protein]tot, A.2). The KD for the protein binding
to peptide at that particular [Ca2+] was obtained by fitting a stoichiometric binding model to the titration curve (A.3). (B) By
repeating this fitting procedure for the titration curves from each row (B.1–2), the KD as a function of [Ca
2+] was obtained (B.3).
Note that the plots in A.3 and B.3 are double-logarithmic.
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The CaM C-domain displayed a Ca2+-dependent affinity (KD from 5.7 mM to 4 nM) for CaMBD2 which was,
on average, 27-fold lower than the full-length CaM affinity in the comparable range of [Ca2+]. Interestingly, the
differences between the full-length CaM and C-domain affinities varied considerably across the measurable
range of [Ca2+] (compare Supplementary Tables S1 and S2). At low nM [Ca2+], the full-length CaM affinity for
CaMBD2 was ∼15-fold higher than for the isolated C-domain, whereas it was ∼50-fold higher at [Ca2+]≥
100 nM. This indicates that the binding of the Ca2+-free CaM C-domain to CaMBD2 is less dependent on the
Figure 4. Example FA signal curves for the titration of RyR2 CaMBD peptides with CaM.
The FA signal from the TAMRA-labeled peptide increased with CaM binding (symbols), and the titration curves were fitted to a
stoichiometric binding model (solid lines)—see ‘Experimental Procedures’.
Figure 5. Ca2+-dependent affinities of CaM for binding to CaMBD1a, 1b, 2, and 3.
The binding model-fitted affinities (KD) are plotted as a function of [Ca
2+]. CaMBD color codings correspond to those indicated
in Figure 2. Note the double logarithmic axes. Error bars represent the 95% confidence intervals of two (CaMBD1a and -1b ± P)
or three (CaMBD2 and -3) replicates.
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presence of the N-domain than the binding of the Ca2+-saturated CaM C-domain. The CaM N-domain bound
to CaMBD2 with three orders of magnitude lower affinity than full-length CaM (at [Ca2+] from 0.8 to 1.6 mM,
for CaMBD2 where comparison was possible).
Observations similar to those for CaMBD2 were made for CaMBD3. For the interaction between the isolated
CaM C-domain and CaMBD3, the Ca2+-dependent affinities (KD from 4 mM to ∼30 nM) were, on average,
36-fold lower than for full-length CaM, but ranging from ∼6-fold lower to ∼70-fold lower when [Ca2+] was raised
from low nM to ≥100 nM. Also for CaMBD3, the isolated CaM N-domain exhibited a three orders of magnitude
lower affinity for binding than full-length CaM (at a [Ca2+] of 0.4 mM where comparison was possible).
The observation that either isolated CaM domain had markedly lower affinity for binding to CaMBD2 and
-3 than full-length CaM showed that both domains contributed to the binding of full-length CaM to either
peptide. On the other hand, the contributions from each domain appeared far from equal. Thus, the CaM
C-domain was the main contributor to the binding of intact CaM to both CaMBD2 and -3. In addition, the
CaM C-domain bound to CaMBD2 with, on average, 9-fold higher affinity than to CaMBD3 in the [Ca2+]
range from 0.1 to 400 mM. Hence, the isolated CaM C-domain showed a clear preference for CaMBD2 over
CaMBD3 across the physiological [Ca2+]. Importantly, the opposite preference was observed for the CaM
N-domain in the measurable [Ca2+] range from 0.4 to 400 mM, where it bound to CaMBD3 with an average of
4.5-fold higher affinity than to CaMBD2.
Substitution of Trp-3587, but not Phe-3603, with Ala impairs CaM binding to
CaMBD2
In the crystal structure of the CaM/RyR1CaMBD2 complex, the RyR2-equivalent Trp-3587 is an anchor site
for the CaM C-domain, and RyR2 Phe-3603 is an anchor site for the CaM N-domain. We compared CaM
titrations in the presence of the CaMBD2 peptide with titrations using peptides with either a Trp-3587-Ala
(CaMBD2(W/A)) or a Phe-3603-Ala (CaMBD2(F/A)) substitution (Figure 7 and Supplementary Tables S1 and
S2). The Ala substitution of Trp-3587 in CaMBD2 had a marked effect on CaM binding. Full-length CaM
exhibited an average 30-fold lower affinity for CaMBD2(W/A), compared with CaMBD2 across the entire range
of [Ca2+]. Moreover, the binding affinity was too weak to be measured when titrating CaMBD2(W/A) with the
isolated CaM N- or C-domain (KD > 5 mM, data not shown). This reduction in affinity of both CaM domains
for CaMBD2(W/A) reveals that when isolated, both CaM domains prefer to bind around Trp-3587.
In contrast with the observations made for the CaMBD2(W/A) peptide, the Phe-3603-Ala substitution in
CaMBD2 hardly affected the binding of CaM. There were no significant differences between the binding of full-
length CaM or individual CaM domains to CaMBD2(F/A), compared with their binding to CaMBD2.
However, at [Ca2+] > 1 mM, a trend towards slightly reduced or increased affinity of CaMBD2(F/A) was
Figure 6. Ca2+-dependent affinities of CaM N- and C-domains for binding to CaMBD2 and -3.
The binding model-fitted affinities (KD) are plotted as a function of [Ca
2+]. CaMBD color codings correspond to those indicated
in Figure 2. Note the double logarithmic axes. Error bars represent the 95% confidence intervals of two (CaMBD3) or three
(CaMBD2) replicates.
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apparent for full-length CaM and the isolated C-domain, respectively (Figure 7). Hence, these results confirmed
RyR2 Trp-3587 as a main CaM-binding determinant both at low and high [Ca2+], and suggested a much
smaller contribution from Phe-3603 to the CaM–CaMBD2 interaction.
Ca2+ affinities of CaM when complexed to each of the four RyR2 CaMBDs
We and others have previously demonstrated that CaM binds Ca2+ with higher affinity when bound to
CaMBD2, compared with free CaM [10,45]. The experimental set-up used in this study allowed us to extend
the analysis and estimate the CaM affinity for Ca2+ in the presence of each of the four CaMBDs. FA curves for
the titration of protein–peptide complexes with [Ca2+] at CaM to peptide ratios >1 (excess of CaM) were
extracted from the data and fitted to an empirical Hill model for Ca2+ binding to CaM (Figure 8 and
Supplementary Table S3) (see ‘Experimental Procedures’ for details).
The CaM affinity for Ca2+ when in complex with each CaMBD was expressed as the apparent [Ca2+]
required to saturate half of the CaM Ca2+- binding sites (appKD). CaM showed distinct affinities for binding
Ca2+ when bound to either CaMBD1a, -1b, -1b + P, -2, or -3 as evident from the Ca2+ titration curves and cor-
responding appKD values (Figure 8A and Supplementary Table S3). CaM displayed a 3.4-fold higher affinity
for Ca2+ when complexed with CaMBD2 compared with CaMBD3 (appKD 20 vs. 67 nM) and a markedly
lower Ca2+ affinity when complexed with CaMBD1a, -1b, or -1b + P (appKD 2.1, 1.0, and 1.5 mM, respectively).
The appKD values were also fitted for the individual CaM domains bound to CaMBD2 or -3 for comparison
with those of full-length CaM (Figure 8B and Supplementary Table S3). The CaM C-domain/CaMBD2
complex had a ∼2-fold lower affinity for Ca2+ compared with full-length CaM/CaMBD2 (appKD 20 vs.
36 nM). On the other hand, the CaM N-domain/CaMBD2 complex had a 60-fold lower affinity for Ca2+ than
full-length CaM/CaMBD2 (appKD 20 nM vs. 1.2 mM). Notably, the affinity of the isolated CaM N-domain for
Ca2+ when bound to CaMBD2 most likely reflects binding around Trp-3587 and not its putative binding site
around Phe-3603 [7,35]. Similar to the observation for CaMBD2, the CaM C-domain/CaMBD3 complex
showed a ∼2-fold lower affinity for Ca2+ compared with full-length CaM/CaMBD3 (appKD 67 vs. 130 nM)
(Figure 8B and Supplementary Table S3). Moreover, the CaM N-domain/CaMBD3 complex had a 6.7-fold
lower affinity for Ca2+ than full-length CaM/CaMBD3 (appKD 67 nM vs. 0.45 mM).
Investigation on the effect of changing the hydrophobic anchor sites of CaMBD2 revealed that the
Trp-3587–Ala substitution markedly impaired Ca2+ binding to the CaM/CaMBD2(W/A) complex as the appKD
was ∼14-fold lower than for CaM/CaMBD2 (KD 0.36 mM vs. 25 nM) (Figure 8C and Supplementary Table S3).
The affinity of both CaM domains for CaMBD2(W/A) was too low to determine the Ca2+ affinity of the
complexes. In contrast with CaM/CaMBD2(W/A), there was only a minor decrease in the Ca2+ affinity of the
CaM/CaMBD2(F/A) complex compared with CaM/CaMBD2 (KD 38 vs. 25 nM). Curiously, a minor increase in
the Ca2+ affinity of the CaM C-domain (KD 41 vs. 54 nM) was apparent when substituting Phe-3603 to Ala,
whereas no difference was observed for the CaM N-domain/CaMBD2(F/A) complex (Figure 8D).
A B
Figure 7. Effects of changing CaMBD2 Trp3587 and Phe3603 anchor residues to Ala on CaM binding.
Effects of mutating RyR2 CaMBD2 anchor residues on the Ca2+-dependent affinities of (A) full-length CaM and (B)
N- and C-domains for binding to CaMBD2. The binding model-fitted affinities (KD) are plotted as a function of [Ca
2+].
Note the double logarithmic axes. Error bars represent the 95% confidence intervals of two replicates.
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Discussion
In this study, we used a two-dimensional titration assay in which the concentration of CaM was varied across
columns and the Ca2+ concentration was varied across rows in a microtiter plate set-up (Figure 3) [37]. The
row-wise titration with CaM was used to measure the CaM affinity for binding to RyR2 CaMBD peptides at 16
different Ca2+ concentrations. Experiments comparing full-length CaM with isolated CaM domains clearly
showed that the CaM C-domain had a higher affinity for binding to CaMBD2 and -3, and therefore partially
masked the contribution from the N-domain in full-length CaM (Figures 5 and 6, and Supplementary
Tables S1 and S2). However, the CaM N-domain did contribute to the interaction with CaMBD2 and -3 as
evident from full-length CaM having a higher affinity for either peptide than the isolated CaM C-domain
(Figures 5 and 6, and Supplementary Tables S1 and S2).
Of the four RyR2 CaMBDs investigated, CaM had high affinities for CaMBD2 and CaMBD3, that increased
with increasing [Ca2+]. Consistent with our results, Lau et al. [28] previously demonstrated a large increase in
the CaM affinity for both CaMBD2 and -3 when comparing apo- and Ca2+-saturating conditions. Here, we
demonstrate that CaM bound to CaMBD2 with higher affinity than to CaMBD3 in the range of [Ca2+] where
we could reliably fit the data (13–200 nM [Ca2+]). Titrations with individual CaM domains revealed that this
preference was mediated by the C-domain (Figure 6), which displayed higher affinity for CaMBD2 over
A B
C D
Figure 8. Visualization of Ca2+ binding to CaM/CaMBD complexes.
Ca2+-binding curves (normalized FA signal as a function of [Ca2+]) are shown for full-length CaM/CaMBD complexes (A), for
isolated CaM domain/CaMBD2 and -3 complexes (B), and for full-length CaM/CaMBD2 (C) or isolated CaM domains/CaMBD2
complexes (D) with CaMBD2 anchor residues changed to Ala. Solid lines show the fit of a generic Hill model for estimating
CaM/CaMBD complex affinities for Ca2+ (see Supplementary Table S3).
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CaMBD3 at all Ca2+ concentrations higher than 25 nM. This implies that the C-domain preferentially binds to
CaMBD2 and thus leaves CaMBD3 available for a potential N-domain interaction (Figure 9). A potential
CaM-mediated bridging of CaMBD2 and CaMBD3 was further supported by the higher affinity of the isolated
CaM N-domain for binding to CaMBD3 compared with CaMBD2 at all Ca2+ concentrations tested. Lau et al.
[28] made the same observations under Ca2+-free and -saturating conditions.
CaMBD2 is known to be pivotal for CaM-dependent inhibition of RyR channels and the RyR2 CaMBD2
Trp-3587 residue has been identified as the instrumental hydrophobic anchor for the binding of the CaM
C-domain [6,8,10,15,28,32]. Similarly, Phe-3603 within RyR2 CaMBD2 was shown to be the hydrophobic
anchor for the CaM N-domain in the crystal structure of the CaM/RyR1CaMBD2 complex [35]. In our experi-
ments, the Trp-3587–Ala substitution prominently decreased the CaM affinity for CaMBD2 for both full-length
CaM and the CaM C-domain across all [Ca2+] tested. This supports a key role of the Trp-3587 residue for the
CaMBD2 interaction with the CaM C-domain in both the apo- and Ca2+-saturated state. Surprisingly, the
Trp-3587 substitution to Ala also diminished the CaMBD2 affinity for the CaM N-domain, demonstrating that
the CaM N-domain preferentially binds to the Trp-3587 site in the absence of the CaM C-domain. However,
we do not anticipate this to be of physiological relevance, as the C-domain in the full-length CaM will outcom-
pete the N-domain for binding to Trp-3587. An exception may be the presence of arrhythmogenic mutations
where the C-domain Ca2+ binding is disrupted also in the presence of CaMBD2 [10].
Substitution of the proposed CaM N-domain anchor, Phe-3603-Ala, only marginally decreased the affinity
of CaMBD2 for full-length CaM. Interestingly, this mutation marginally increased the affinity for the isolated
CaM C-domain at [Ca2+] > 1 mM. These results suggest a potential contribution of RyR2 Phe-3603 to the CaM
C-domain/CaMBD2 interaction at some, likely elevated, [Ca2+]. The Phe-3603 substitution to Ala caused no
change in the CaM N-domain affinity for CaMBD2. This supported that the CaM N-domain prefers to bind
around the Trp-3587 anchor site when not competing with the C-domain, and indicated that Phe-3603 is not
a prerequisite for the CaM N-domain binding to RyR2 CaMBD2. The findings of this study were consistent
with the ITC results presented by Lau et al. [28], concerning the reduced affinity of full-length CaM and its
Figure 9. Proposed binding scheme for CaM regulation of RyR2 with increasing levels of cytosolic Ca2+.
RyR2 CaMBD2 is indicated with a green α-helix and Ca2+ with dark spheres. When binding to RyR2, the CaM N-domain is
highlighted in red and the C-domain in purple. Free domains are shown in white. At essentially Ca2+-free conditions (3 nM Ca2+,
upper row), the CaM C-domain may bind to CaMBD2, involving Trp-3587, or to another RyR2 CaMBD (orange α-helix), such as
CaMBD3. However, at resting cytosolic Ca2+ levels (∼100 nM, middle row), a Ca2+-saturated CaM C-domain binds to the
CaMBD2 anchor residue, Trp-3587, and the apo-N-domain may interact with another CaMBD or may remain free. At cytosolic
Ca2+ levels ∼1 mM and higher (illustrated as >10 mM, lower row), the CaM C-domain remains anchored to CaMBD2 Trp-3587,
whereas the N-domain now binds Ca2+ and interacts with another site on RyR2 (e.g. CaMBD3), or clamps down on CaMBD2
Phe-3603.
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isolated C-domain for CaMBD2 when Trp-3587 was substituted with Ala. In general, our results indicate that
data obtained from using individual CaM domains should be interpreted with caution. Given the structural
and functional similarity between the CaM N- and C-domains, the isolated N-domain may preferentially bind
to sites natively occupied by the C-domain (or vice versa) when otherwise using full-length CaM.
Compared with CaMBD2 and -3, CaM displayed an approximately three orders of magnitude lower affinity
for binding to CaMBD1a and -1b. Thus, CaM would appear to bind preferentially to CaMBD2 or -3 by a wide
margin compared with CaMBD1a and -1b, and under any [Ca2+] condition. However, since these CaMBDs are
located in close proximity to the CaM-binding groove of RyR (Figure 2), their effective concentration relative
to a proximate CaM may be very high. Accordingly, these two low-affinity CaMBDs may serve as secondary
‘bridging’ CaM-binding sites under some Ca2+ conditions or in certain RyR conformations, together with a
high-affinity tethering site like that of CaMBD2. Noteworthy, Ser-2031 within RyR2 CaMBD1b is a target for
phosphorylation by β-adrenergic-stimulated protein kinase A (PKA) [46,47] (Figure 1 and Table 1). Our results
demonstrated a small decrease in the CaM affinity for the CaMBD1b peptide when using a Ser-2031 phos-
phorylated, compared with nonphosphorylated CaMBD1b. Hence, PKA-mediated Ser-2031 phosphorylation
could potentially affect CaM’s inhibition of RyR2, if CaMBD1b is indeed a functionally relevant RyR2 CaMBD
at increased [Ca2+].
Aside from measuring the Ca2+-dependent propensity of CaM binding to the individual RyR2 CaMBD pep-
tides, we also determined the CaM affinities for Ca2+ in the presence of the individual CaMBDs (expressed as
an apparent KD, appKD) (Supplementary Table S3 and Figure 8A–D). In the presence of CaMBD2, full-length
CaM had an appKD of 20 nM, and the individual CaM C-domain had a similar appKD of 36 nM (Figure 8A,
B). This is in full agreement with our previous findings, measuring domain-wise intrinsic fluorescence (appKD
of 30 nM for the CaM C-domain in the presence of CaMBD2) [10,21]. Since the cytosolic [Ca2+] is maintained
above 100 nM in the cardiomyocyte even at resting conditions, this strongly suggests that the C-domain of
CaM is bound to CaMBD2 in a Ca2+-saturated state throughout the excitation contraction cycle. The Ca2+
affinity of the CaM N-domain in the presence of CaMBD2, however, was much lower (appKD 1.2 mM).
Although this affinity reflects the CaM N-domain bound around Trp-3587, and not Phe-3603 (see above), it is
highly comparable to the Ca2+ affinity previously measured for the CaM N-domain in the context of full-length
CaM using intrinsic protein fluorescence (appKD of 0.8 mM for the CaM N-domain in the presence of
CaMBD2) [10,21]. In the presence of CaMBD3, full-length CaM displayed an appKD of 67 nM, and the
isolated CaM C-domain an appKD of 130 nM, thus slightly lower Ca
2+ affinities than in the presence of
CaMBD2 (Figure 8A,B). Intriguingly, the isolated CaM N-domain displayed an appKD of 0.45 mM in the
presence of CaMBD3 and thus a higher apparent Ca2+ affinity than in the presence of CaMBD2
(Figure 8B).
Altogether, our results add to our previously proposed model for the CaM–RyR2 interaction [10,21]: the
CaM C-domain is constitutively anchored to CaMBD2 around Trp-3587 in a Ca2+-saturated state, whereas the
CaM N-domain functions as the primary resident Ca2+ sensor under physiological Ca2+ oscillations (Figure 9).
During cardiac excitation, when [Ca2+] rises above ∼0.5 mM, the CaM N-domain may bind to CaMBD3
(Figure 9). This would bridge RyR2 CaMBD2 and -3, similar to the observations made for the Ca2+-dependent
CaM bridging of noncontiguous regions of both the voltage-gated Na+ (NaV1.5) and Ca
2+ channels (CaV1.2)
[48–50]. Alternatively, if RyR2 CaMBD3 is not available for a CaM N-domain interaction, it is conceivable that
at higher [Ca2+], the CaM N-domain may bind to CaMBD1a or -1b or clamp down onto the CaMBD2 around
Phe-3603, or even bind a yet unidentified RyR2 site outside these regions (Figure 9). Whether CaMBD1a, -1b,
and -3 are functionally relevant RyR2 CaMBDs remain to be investigated, but this study provides general
guidelines for under which Ca2+ conditions these CaMBDs could be relevant.
CaM regulation of RyR2 Ca2+ release is essential for maintaining cardiac contraction cycles, and a thorough
understanding of the molecular details of this regulation is important for evaluating the potential arrhythmo-
genic effects of novel CaM mutations [7,31,51]. In our binding model, the Ca2+-saturated CaM C-domain is
pivotal for RyR2 inhibition, even at diastolic Ca2+ levels, and its high affinity for binding to CaMBD2 and for
binding Ca2+ is therefore crucial. Subsequent Ca2+ binding to the CaM N-domain at elevated systolic Ca2+
levels changes CaM’s binding mode and enhances channel inhibition. This is in accordance with the previously
reported CaM-dependent decrease in RyR2 activity, especially above ∼0.5 mM Ca2+, as determined by
ryanodine-binding experiments [52]. Finally, the arrhythmogenic CaM N-domain mutation, CaM-N53I (num-
bering without the start-Met), strongly corroborates a key role for the CaM N-domain in conveying informa-
tion about increases in [Ca2+] to RyR2 [35].
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Conclusions
In conclusion, the results presented in this work provide the first report on the Ca2+ dependency of CaM
binding to the four proposed CaMBDs of RyR2. Our data support a domain-wise interaction between CaM
and RyR2 that changes with increasing cytosolic Ca2+ concentrations. The CaM C-domain is constitutively
bound to CaMBD2 in a Ca2+-saturated state, and the CaM N-domain functions as a dynamic Ca2+ sensor, in
the physiological range of Ca2+ concentrations, that can bridge noncontiguous regions of RyR2, such as
CaMBD1a, -1b, or -3, or clamp down onto the Phe-3603 of CaMBD2.
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